Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | VDR | P11473 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.31 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2965277 | 0.81 | KMT2A (0.47) | EPHX2KMT2AMEN1SMN1; SMN2IDO1 | |
| SCHEMBL6496572 | 0.81 | KMT2A (0.33) | KMT2AMEN1 | |
| SCHEMBL6492766 | 0.80 | EPHX2 (0.44) | EPHX2TSHRNPSR1KMT2AMEN1 | |
| Ammonia Solution, Strong SCHEMBL11633437 | 0.79 | KMT2A (0.46) | EPHX2KMT2AMEN1SMN1; SMN2IDO1 | |
| SCHEMBL3433888 | 0.67 | EPHX2 (0.36) | EPHX2TSHRNPSR1 | |
| SCHEMBL6502645 | 0.67 | EPHX2 (0.46) | EPHX2TSHRNPSR1ALDH1A1 | |
| SCHEMBL12430198 | 0.66 | NPSR1 (0.51) | EPHX2TSHRNPSR1KMT2AMEN1 | |
| SCHEMBL10158506 | 0.66 | EPHX2 (0.36) | EPHX2TSHRNPSR1 | |
| SCHEMBL26598035 | 0.66 | CYP17A1 (0.43) | EPHX2TSHRNPSR1KMT2AMEN1 | |
| SCHEMBL26849803 | 0.66 | MEN1 (0.41) | EPHX2TSHRNPSR1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949615-B2 | Monomer having electron-withdrawing group and process for preparing the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-1331216-A1 | MONOMERS HAVING ELECTRON-WITHDRAWING GROUPS AND PROCESSES FOR PREPARING THE SAME | Daicel Chemical Industries, Ltd. (JP) | 2003-07-30 | — | — | EP | disclosed |
| US-20030059710-A1 | Monomer having electron-withdrawing group and process for preparing the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030059710-A1 | Monomer having electron-withdrawing group and process for preparing the same | RFC3, RFC2, MAPRE1 | EPHX2 1930/4885TSHR 783/4885NPSR1 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.